ACTION Trial- Adoptive Cellular Therapy following Dose-Intensified Temozolomide in Newly-diagnosed Pediatric High-grade Gliomas (Phase I)
The purpose of this research study is to learn whether anti-tumor T-cells and anti-tumor DC vaccines can be given safely. Most importantly, this study is also to determine whether the T-cells and DC vaccines can stimulate a person's immune system to fight off the tumor cells in the brain.
To determine the safety of adoptive cellular therapy in pediatric patients with HGG receiving dose intensified TMZ and DC+xALT therapy with and without HSCs. 1) Examine feasibility of completing treatment (administration of at least 3 DC vaccines) in enrolled subjects. 2) Comparison of baseline to post-immunotherapy functional anti-tumor immune responses. 3) Analysis of progression-free survival and overall survival after treatment with DC + xALT therapy with and without HSCs.
Chemotherapy (NOS); Immunotherapy; Radiotherapy; Surgery
Autologous Dendritic Cells (); Autologous Lymphocyte Infusion (); Hematopoietic Progenitor Cells (); Temodal (Temozolomide); Temozolomide ()
Back to top
Please call 1-888-663-3488 for support from a Moffitt representative. New Patients and Healthcare Professionals can submit an online form by selecting the appropriate button below. Existing patients can call 1-888-663-3488. Click here for a current list of insurances accepted at Moffitt.
NEW PATIENTS To request a new patient appointment, please fill out the online form or call 1-888-663-3488.
REFERRING PHYSICIANS Providers and medical staff can refer patients by submitting our online referral form.
Moffit now offers Virtual Visits for patients. If you are eligible for a virtual appointment, our scheduling team will discuss this option further with you.